Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy

被引：0
作者：
DHY Shen
DK Marsee
J Schaap
W Yang
J-Y Cho
G Hinkle
HN Nagaraja
RT Kloos
RF Barth
SM Jhiang
机构：
[1] College of Medicine and Public Health,Department of Physiology and Cell Biology
[2] The Ohio State University,Department of Pathology
[3] College of Medicine and Public Health,Department of Radiology
[4] The Ohio State University,Department of Statistics
[5] College of Medicine and Public Health,Department of Internal Medicine
[6] The Ohio State University,Department of Nuclear Medicine
[7] College of Medicine and Public Health,undefined
[8] The Ohio State University,undefined
[9] College of Medicine and Public Health,undefined
[10] The Ohio State University,undefined
[11] Tri-Service General Hospital,undefined
[12] National Defense Medical Center,undefined
来源：
Gene Therapy | 2004年 / 11卷
关键词：
sodium iodide symporter; radionuclide therapy; brain neoplasm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. In this study, we show that: (1) the therapeutic effectiveness of 131I in prolonging the survival time of rats bearing F98/hNIS gliomas is dose- and treatment-time-dependent; (2) the number of remaining NIS-expressing tumor cells decreased greatly in RG2/hNIS gliomas post 131I treatment and was inversely related to survival time; (3) 8 mCi each of 125I/131I is as effective as 16 mCi 131I alone, despite a smaller tumor absorbed dose; (4) 188ReO4, a potent β− emitter, is more efficient than 131I to enhance the survival of rats bearing F98/hNIS gliomas. These studies demonstrate the importance of radiopharmaceutical selection, dose, and timing of treatment to optimize the therapeutic effectiveness of NIS-targeted radionuclide therapy following gene transfer into gliomas.
引用
收藏
页码：161 / 169
页数：8
相关论文
共 81 条
[1]  
Dai G(1996)Cloning and characterization of the thyroid iodide transporter Nature 379 458-460
[2]  
Levy O(1996)Cloning of the human sodium lodide symporter Biochem Biophys Res Commun 226 339-345
[3]  
Carrasco N(1997)Iodide uptake and experimental Endocrinology 138 4493-4496
[4]  
Smanik PA(1999)I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene Cancer Res 59 661-668
[5]  
Shimura H(2002)Radioisotope concentrator gene therapy using the sodium/iodide symporter gene Gene Therapy 9 1139-1145
[6]  
Mandell RB(2002) imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas Prostate 50 170-178
[7]  
Mandell LZ(2000) expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer Cancer Res 60 3484-3492
[8]  
Link CJ(2000)Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy J Nucl Med 41 1898-1904
[9]  
Cho JY(2001)Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy J Nucl Med 42 317-325
[10]  
La Perle KM(1999)Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells Cancer Res 59 2136-2141
123456789